Reproductive Health - Research and Data from KFF

What Are the Exceptions to State Abortion Bans?

May 18, 2023

News Release

A new KFF analysis reviews exceptions to abortion bans and describes how the stated aim to provide life-saving and health-preserving abortion care may not be achieved in practice. Abortion is currently banned in 14 states and many other states have attempted to ban or severely restrict abortion access. Exceptions to state abortion bans generally fall into four general categories: to prevent the death of the pregnant person, when there is risk to the health of…

Update on the Status of Medication Abortion and the Courts

Apr 21, 2023

Policy Watch

This policy watch explains the April 21, 2023 United States Supreme Court's ruling on Alliance for Hippocratic Medicine v. FDA, a case challening the FDA's approval of mifepristone, the medication abortion pill.

Q & A: Implications of Two Conflicting Federal Court Rulings on the Availability of Medication Abortion and the FDA’s Authority to Regulate Drugs

Apr 8, 2023

Policy Watch

This policy watch explains the two conflicting rulings on the provision of mifepristone issued by two separate District Courts on April 7, 2023, Alliance for Hippocratic Medicine v. FDA and State of Washington v. United States Food and Drug Administration.

Q&A: Implications of the Ruling on the ACA’s Preventive Services Requirement

Apr 4, 2023

Policy Watch

This post summarizes some of the key issues related to the U.S. District Court's March 30 ruling in Braidwood Management v. Becerra, which imposes new limits on the government's ability to enforce preventive service requirements nationwide.

Who Uses Telecontraception and Why? A Closer Look at Clients of Four Telecontraception Companies

Apr 4, 2023

Issue Brief

Based on the findings of a nonprobability sample of 6,000 survey respondents from four telecontraception companies, this brief presents a snapshot of telecontraception users and their reasons for using these platforms.

Medication Abortion in the Courts: What’s at Stake?

Mar 8, 2023

News Release

Access to medication abortion has emerged as a central issue following the Dobbs decision overturning Roe v. Wade. There is ongoing litigation in four federal cases about the FDA’s approval and regulation of mifepristone, one of the two drugs used in medication abortion. Mifepristone, approved by the FDA in 2000, has a long record of safety and effectiveness and has been used by more than 5 million people in the United States. In the most…

Many Women Use Preventive Services, but Gaps in Awareness of Insurance Coverage Requirements Persist: Findings from the 2022 KFF Women’s Health Survey

Feb 22, 2023

Issue Brief

This brief presents findings from the 2022 KFF Women’s Health Survey on women’s receipt of cancer screenings and other preventive services and differences between subgroups of women. We also present data on women’s and men’s awareness of federal requirements for private insurance coverage of preventive services.

The Public, Including Women of Childbearing Age, Are Largely Confused About the Legality of Medication Abortion and Emergency Contraceptives in Their States

Feb 1, 2023

News Release

More than six months since the Supreme Court issued their Dobbs decision which overturned Roe v. Wade, there is widespread public confusion about the medication abortion pill and whether it is legal at the state level, according to the latest KFF Health Tracking Poll. The poll also finds many are unsure about the legality of emergency contraceptive pills, sometimes called morning after pills or “Plan B,” and whether the pills can end a pregnancy. Across…

KFF Health Tracking Poll: Early 2023 Update On Public Awareness On Abortion and Emergency Contraception

Feb 1, 2023

Feature

Following the FDA approval of retail pharmacies carrying and distributing medication abortion, this poll finds that the public's awareness and knowledge of emergency contraception and medication abortion is still lacking, especially among respondents living in states with full abortion bans.

KFF Health Tracking Poll December 2022: The Public’s Health Care Priorities For The New Congress

Dec 20, 2022

Feature

This survey looks at the public's health care priorities for the new Congress, including price transparency, mental health, abortion, Medicaid, and health costs. It also looks at the public's views of the main health provisions in the Inflation Reduction Act (IRA), including on Medicare drug prices.

Topics

Policy Research

Polling

Health News

Data & Features

For Media

About

View the Latest: Reproductive Health

Filter